Definium Therapeutics
DFTX
151 hedge funds and large institutions have $299M invested in Definium Therapeutics in 2024 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 39 increasing their positions, 24 reducing their positions, and 27 closing their positions.
282% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $3.77M
63% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 27
63% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 24
12% more funds holding
Funds holding: 135 → 151 (+16)
9% less capital invested
Capital invested by funds: $327M → $299M (-$28.2M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
26.45% less ownership
Funds ownership: 84.24% → 57.79% (-26%)
Top Buyers
| 1 |
BlackRock
New York
|
+$40.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.7M |
| 3 |
CC
Commodore Capital
New York
|
+$11.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.84M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
T. Rowe Price Associates
Baltimore,
Maryland
| – | +$201K | +22,952 | New |
|
DFTX Hedge Fund Activity: Q2 2024 in Review
151 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2024, worth a combined $299M — down 8.6% from $327M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new DFTX positions and 27 closed out — a net gain of 17 holders — while 39 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $40.1M. The largest seller was Great Point Partners, exiting entirely with an estimated $18.8M sold.
- 151 institutional investors held Definium Therapeutics (DFTX) as of Q2 2024, up from 135 in Q1 2024.
- Funds reported $299M of Definium Therapeutics stock for Q2 2024, down 8.6% quarter-over-quarter.
- 44 funds opened new Definium Therapeutics positions in Q2 2024 and 27 closed out, a net change of +17 holders.
- The largest Definium Therapeutics buyer in Q2 2024 was BlackRock, an estimated $40.1M added.
- The largest Definium Therapeutics seller in Q2 2024 was Great Point Partners, an estimated $18.8M sold.
Based on aggregated 13F filings for Q2 2024.